New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
05:37 EDTHTWR, THORThoratec downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Thoratec to Neutral citing the weaker LVAD market and limited visibility following the company's Q2 results. The firm lowered its price target for shares to $28 from $38. Goldman keeps a Sell rating on peer HeartWare (HTWR) and lowered its price target on the name to $73 from $75.
News For THOR;HTWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
07:40 EDTHTWRHeartWare price target raised to $105 from $90 at Leerink
Subscribe for More Information
February 26, 2015
07:03 EDTHTWRHeartWare reports 737 HeartWave Ventricular Assist Systems sold globally
U.S. revenue, generated through the sale of 382 units during the fourth quarter of 2014, was $41.5 million, a 60% increase from $25.9 million in the fourth quarter of 2013.
07:02 EDTHTWRHeartWare reports Q4 non-GAAP EPS (41c), consensus (59c)
Subscribe for More Information
February 23, 2015
07:28 EDTHTWRHeartWare recall should not have material impact long-term, says Canaccord
Canaccord does not believe the voluntary recall issued by HeartWare should not have any material impact on its business long-term, as the serious event rate is relatively low. The recall pertains to a previously known issue and is in effect a continuation of its 2013 corrective action, Canaccord said. The firm reiterated its Buy rating and $115 price target on HeartWare shares.
February 20, 2015
16:35 EDTHTWRHeartWare issues recall of older HeartWare clinical trial controllers
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use